Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of “Buy” from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been assigned an average rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.60.

Several analysts have recently commented on HUMA shares. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Humacyte in a research note on Tuesday, July 2nd. BTIG Research upped their price target on Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Benchmark reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research report on Thursday, September 5th.

Humacyte Stock Performance

NASDAQ:HUMA opened at $5.39 on Tuesday. The stock has a market capitalization of $643.30 million, a P/E ratio of -5.39 and a beta of 1.47. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte has a 1 year low of $1.96 and a 1 year high of $9.97. The firm has a 50 day moving average of $6.93 and a 200-day moving average of $5.52.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, sell-side analysts anticipate that Humacyte will post -1.09 EPS for the current fiscal year.

Insider Activity

In other news, Director Brady W. Dougan sold 352,112 shares of the business’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the transaction, the director now directly owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Laura E. Niklason sold 277,090 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the sale, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at approximately $26,070,049.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the transaction, the director now owns 3,677,262 shares in the company, valued at $23,350,613.70. The disclosure for this sale can be found here. Insiders have sold a total of 1,192,785 shares of company stock valued at $7,969,339 in the last 90 days. 23.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HUMA. The Manufacturers Life Insurance Company raised its stake in shares of Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after purchasing an additional 8,557 shares during the period. Millennium Management LLC grew its holdings in shares of Humacyte by 504.3% during the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after buying an additional 1,334,641 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Humacyte in the 2nd quarter valued at approximately $1,550,000. AQR Capital Management LLC lifted its stake in Humacyte by 1,018.4% in the 2nd quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after acquiring an additional 233,422 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after acquiring an additional 450,031 shares during the last quarter. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.